Advances implementation of Transform and Transcend strategic initiative across Operational Excellence and New Technology Commercialization
ROMEOVILLE, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2026.
"In March, we introduced Transform and Transcend to our investor community, the strategic initiative that we began at the end of 2025," commented Kevin Cureton, President and Chief Executive Officer. "Our first quarter results reflect our disciplined execution on this initiative, particularly on our first and foundational pillar, operational excellence. Combined with steady early progress in our efforts to further leverage our intellectual property, expand our addressable market, and evolve our service model to capture greater share of the value chain, Solésence is well positioned to drive long-term, sustainable profitability and growth."
Recent Highlights and Accomplishments
-- Improved gross margin through disciplined execution of first pillar of
Transform & Transcend Initiative: Operational Excellence.
-- Expanded OTC claims with commercialization of new platform technologies:
WHSPR$(TM)$ and Chromalüm(TM).
-- Added financial executive Marc James as new independent Director.
Laura Riffner, Chief Financial Officer, added, "In the first quarter, Solésence's investments focused on its operational infrastructure, including employee training and organizational restructuring which created near-term pressure on profitability but also resulted in improved efficiency and reduced labor costs across the business. We expect this will position us for improved operational and financial results as we move through the year."
First Quarter 2026 Financial Highlights
-- Revenue for the first quarter was $13.0 million, compared to $14.6
million for the same period in 2025.
-- Gross profit in the first quarter was $3.3 million, compared to $3.4
million for the same period in 2025.
-- Gross margin in the first quarter was 26%, compared to 23% for the same
period in 2025.
-- Net loss for the first quarter was approximately $0.8 million, compared
to net income of approximately $0.08 million for the same period in 2025.
Conference Call
Solésence will host its first quarter conference call on Tuesday, May 12, 2026, at 7:30 a.m. CT, 8:30 a.m. ET, to discuss its financial results and provide a business and financial update. On the call will be Kevin Cureton, President and Chief Executive Officer, and Laura Riffner, Chief Financial Officer.
Webcast Link: https://edge.media-server.com/mmc/p/t9uyyvcs
Dial-In Link: https://register-conf.media-server.com/register/BI8309d9a33aea468ab429e32ef4434b33
To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the option to have the system dial-out to you once the conference call begins. If you forget your PIN prior to the conference call, you can simply re-register.
The call may also be accessed through the Company's investor relations website, at https://ir.solesence.com/. Please join the conference call at least five minutes before the start time.
FINANCIAL RESULTS AND NON-GAAP INFORMATION
Use of Non-GAAP Financial Information
Solésence believes that the presentation of results excluding certain items, such as non-cash equity compensation charges, provides meaningful supplemental information to both management and investors, facilitating the evaluation of performance across reporting periods. The Company uses these non-GAAP measures for internal planning and reporting purposes. These non-GAAP measures are not in accordance with, or an alternative for, Generally Accepted Accounting Principles ("GAAP") and may be different from non-GAAP measures used by other companies. The presentation of this additional information is not meant to be considered in isolation or as a substitute for net income or net income per share prepared in accordance with GAAP.
About Solésence, Inc.
Solésence, Inc. (Nasdaq: SLSN) is a leader in scientifically-driven health care solutions across beauty and life science categories. With a mission to deliver joy through innovation, inclusivity and the science of beautiful skin, we have redefined mineral-based sun protection by maximizing transparency, effectiveness, aesthetics, and wearability -- empowering individuals to embrace beauty on their own terms. Combining best-in-class skin health solutions with the celebration of self-care, we allow brands to deliver unique product claims and attributes by seamlessly integrating protection, prevention, and treatment technologies into daily use products. Learn more at solesence.com.
Forward-Looking Statements
This press release contains words such as "expects," "shall," "will," "believes," and similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company's current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company's results of operations, performance, and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, without limitation, the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company's dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company's engineered materials, ingredients, and fully formulated products; the Company's manufacturing capacity and product mix flexibility in light of customer demand; the Company's limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company's dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; the impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable; the ability of the Company to maintain an appropriate electronic trading venue; and other factors described in the Company's Form 10-K filed March 31, 2026. In addition, the Company's forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies.
Media Contact:
media@solesence.com
Investor Relations Contact:
investors@solesence.com
SOLESENCE, INC
CONSOLIDATED BALANCE SHEETS
(Unaudited Consolidated Condensed)
(in thousands except share and per share data)
March 31, December 31,
2026 2025
ASSETS (Unaudited)
----------------------------- ------------------------
Current assets:
Cash $ 573 $ 1,288
Trade accounts
receivable 7,246 7,642
Allowance for
credit losses (867) (806)
Trade
accounts
receivable,
net 6,379 6,836
Inventories, net 17,559 18,511
Prepaid expenses
and other
current assets 1,902 2,141
----- ------------------ ----------------
Total current
assets 26,413 28,776
Equipment and
leasehold
improvements,
net 14,746 14,329
Operating
leases, right
of use 6,598 6,913
Other assets,
net 37 37
Total assets $ 47,794 $ 50,055
===== ================== ================
LIABILITIES AND STOCKHOLDERS' EQUITY
Current
liabilities:
Line of credit,
accounts
receivable,
related party 3,047 4,767
Current portion
of operating
lease
obligations 1,296 1,255
Accounts payable 4,672 4,098
Deferred revenue 1,165 930
Accrued expenses 2,511 2,879
Total current
liabilities 12,691 13,929
----- ------------------ ----------------
Long-term
portion of
operating lease
obligations 7,440 7,798
Long-term
portion of line
of credit,
inventory,
related party 9,500 9,500
Long-term
portion of
debt, related
parties 1,000 1,000
Asset retirement
obligations 196 194
Total long-term
liabilities 18,136 18,492
----- ------------------ ----------------
Stockholders'
equity:
Preferred stock,
$.01 par value,
24,088 shares
authorized and
no shares issued
and outstanding - -
Common stock,
$.01 par value,
95,000,000
shares
authorized;
70,632,445 and
70,614,045
shares issued
and outstanding
on March 31,
2026 and
December 31,
2025,
respectively 706 706
Additional
paid-in
capital 115,665 115,566
Accumulated
deficit (99,404) (98,638)
Total
stockholders'
equity 16,967 17,634
----- ------------------ ----------------
Total
liabilities and
shareholders'
equity $ 47,794 $ 50,055
===== ================== ================
SOLESENCE, INC
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited Consolidated Condensed)
(in thousands except share and per share data)
Three months ended
March 31,
2026 2025
Revenue:
Product revenue $ 12,919 $ 14,575
Other revenue 38 50
---------- ----------
Net revenue 12,957 14,625
Cost of revenue 9,620 11,243
---------- ----------
Gross profit 3,337 3,382
Operating expense:
Research and development expense 1,042 1,018
Selling, general and administrative
expense 2,799 2,108
---------- ----------
Net (loss) income from operations (504) 256
Interest income
Interest expense 263 176
Other nonoperating income 1 -
---------- ----------
Net (loss) income before provision for
income taxes (766) 80
Provision for income taxes - -
Net (loss) income $ (766) $ 80
========== ==========
Net (loss) income per share-basic $ (0.01) $ -
========== ==========
Weighted average number of common shares
outstanding - basic 70,625,494 70,103,279
========== ==========
Net (loss) income per share-diluted $ (0.01) $ -
========== ==========
Weighted average number of common shares
outstanding - diluted 70,625,494 72,632,116
========== ==========
SOLESENCE, INC
CONSOLIDATED STATEMENTS OF OPERATIONS - EXPANDED SCHEDULE
(Unaudited Consolidated Condensed)
(in thousands except share and per share data)
Three months ended
March 31,
2026 2025
------------ -------------
Revenue:
Product revenue $ 12,919 $ 14,575
Other revenue 38 50
---------- ----------
Net revenue 12,957 14,625
Cost of revenue detail:
Depreciation 302 216
Non-Cash equity compensation 20 27
Other costs of revenue 9,298 11,000
---------- ----------
Cost of revenue 9,620 11,243
---------- ----------
Gross profit 3,337 3,382
Operating expense:
Research and development expense
detail:
Depreciation 4 4
Non-Cash equity compensation 18 27
Other research and development expense 1,020 987
---------- ----------
Research and development expense 1,042 1,018
Selling, general and administrative
expense detail:
Depreciation and amortization 6 6
Non-Cash equity compensation 46 73
Other selling, general and
administrative expense 2,747 2,029
---------- ----------
Selling, general and administrative
expense 2,799 2,108
---------- ----------
Net (loss) income from operations (504) 256
Interest income
Interest expense 263 176
Other nonoperating income 1 -
---------- ----------
Net (loss) income before provision for
income taxes (766) 80
Provision for income taxes - -
Net (loss) income $ (766) $ 80
========== ==========
Non-GAAP Disclosure (see note regarding
Non-GAAP disclosures):
----------------------------------------- ------------ -----------
Addback Interest, net 263 176
Addback Depreciation/Amortization 312 226
Addback Non-Cash Equity Compensation 84 127
Subtract Non-Cash Other Income - -
---------- ----------
Adjusted EBITDA $ (107) $ 609
========== ==========
(END) Dow Jones Newswires
May 12, 2026 08:00 ET (12:00 GMT)